Needham Reiterates Buy on Vaxcyte, Maintains $58 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Joseph Stringer has reiterated a 'Buy' rating on Vaxcyte (NASDAQ:PCVX) and maintained a price target of $58.
November 07, 2023 | 3:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Joseph Stringer has reiterated a 'Buy' rating on Vaxcyte and maintained a price target of $58, which could potentially boost investor confidence in the stock.
Analyst ratings often influence investor sentiment and can impact a stock's price. In this case, the reiteration of a 'Buy' rating and a maintained price target by a Needham analyst could potentially boost investor confidence in Vaxcyte, leading to a positive short-term impact on the stock's price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100